Business / Finance

RSS

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. announced it has priced $200 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission on January 31, 2011. In addition, Savient has granted the underwriters an option to purchase up to an additional $30 million aggregate principal amount of Notes, solely to cover over-allotments.

1 Feb 2011

Kensey Nash second quarter revenue decreases to $17.4 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second quarter ended December 31, 2010.

1 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

RTI fourth quarter net sales increases to $114.7 million

RTI International Metals, Inc.,, released results today for the fourth quarter and full year of 2010.

1 Feb 2011

Kinetic Concepts fourth quarter net earnings increase 12% to $74.0 million

Kinetic Concepts, Inc. today reported fourth quarter and full year 2010 total revenue of $527.5 million and $2.02 billion, respectively, compared to $526.8 million and $1.99 billion in the corresponding periods of the prior year.

1 Feb 2011

CorVel third quarter earnings per share increases 4% to $0.56

CorVel Corporation today announced earnings per share of $0.56 for the quarter ended December 31, 2010, a 4% increase compared to $0.54 in the same quarter of the prior fiscal year. Earnings per share for the nine months ended December 31, 2010 were $1.82, a 20% increase over the $1.52 earnings per share for the nine months ended December 31, 2009.

1 Feb 2011

Covidien first-quarter net sales increase 5% to $2.77 billion

Covidien plc today reported results for the first quarter of fiscal 2011 (October-December 2010). First-quarter net sales of $2.77 billion increased 5% from the $2.64 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate.

1 Feb 2011

Genzyme, Sanofi-Aventis enter confidentiality agreement

Genzyme Corp. announced today that ongoing discussions with Sanofi-Aventis have progressed to the point where Genzyme's board has authorized the company to enter into a confidentiality agreement with Sanofi-Aventis in order to allow Sanofi to conduct due diligence. Discussions between Genzyme's advisors and Sanofi's advisors and between Genzyme and Sanofi representatives are continuing.

1 Feb 2011

Court rules in favor of Volcano/Axsun against LightLab Imaging

Volcano Corporation said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief.

1 Feb 2011

Masimo amends January 2006 settlement agreement with Covidien

Following today's announcement by Masimo that the company has amended its January 2006 settlement agreement with Covidien, Masimo provides the following additional information.

1 Feb 2011

Duke, LifePoint enter joint venture to improve healthcare delivery for North Carolina community hospitals

Duke University Health System, Inc. and LifePoint Hospitals® have formed DLP Healthcare, LLC (Duke/LifePoint), a joint venture designed to strengthen and improve healthcare delivery throughout North Carolina and the surrounding regions by creating flexible affiliation options for community hospitals.

1 Feb 2011

Quest Diagnostics to repurchase 15.4M shares from GSK affiliate

Quest Diagnostics Incorporated today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics.

From Quest Diagnostics 1 Feb 2011

Valeant announces binding agreement to acquire PharmaSwiss for euro 350 million

Valeant Pharmaceuticals International, Inc. and PharmaSwiss S.A. announced today that they have signed a binding agreement for Valeant to acquire PharmaSwiss, a privately-owned branded generics and over-the-counter pharmaceutical company based in Zug, Switzerland for euro 350 million.

1 Feb 2011

Parker Tennessee accepts to purchase common stock of King Pharmaceuticals at $14.25 per share

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. at a purchase price of $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

1 Feb 2011

Encision reports gross profit margin increase in third quarter of fiscal year 2011

Encision, a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported profitable financial results for its third fiscal quarter ended December 31, 2010.

31 Jan 2011

Alexion announces acquisition of Taligen Therapeutics

Alexion Pharmaceuticals, announced that it has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, Mass.

31 Jan 2011

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that a binding subscription agreement has been executed in relation to share placement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“ASK”). The proposed placement is for the issue of 14,334,080 LCT shares at A$0.12 per share, to raise A$1.72m. This represents a 5% equity stake in LCT, the funds to be received by LCT from ASK not later than 4 March 2011.

31 Jan 2011

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.

30 Jan 2011

Capital Pro-Égaux shares to continue on NEX

Capital Pro-Égaux Inc. announces that trading in its shares will resume on January 28, 2011 on NEX, a new and separate board of the TSX Venture Exchange.

29 Jan 2011